Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Lyell Immunopharma, Inc. (LYEL)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19
   8-K10-K10-K10-K
Revenues  84.710.77.80.7
            Revenue growth  695.1%37.3%1080.5% 
Cost of goods sold  0.00.00.00.0
Gross profit  84.710.77.80.7
            Gross margin  100.0%100.0%100.0%100.0%
Selling, general and administrative   [+]117.389.146.939.2
Research and development   138.7182.263.6
Other operating expenses  154.4-2.3-9.4 
EBITDA   [+] -201.2-207.6-100.8
            EBITDA margin  -220.9%-1888.8%-2677.2%-15347.5%
Depreciation and amortization   13.64.31.3
EBIT   [+]-187.1-214.8-211.9-102.1
            EBIT margin  -220.9%-2016.7%-2732.6%-15538.7%
Interest income  7.11.25.98.1
Other income (expense), net  180.0-36.61.5-35.4
Pre-tax income  0.0-250.2-204.5-129.4
Income taxes  0.00.00.00.0
            Tax rate   0.0%0.0%0.0%
Net income  0.0-250.2-208.1-130.5
            Net margin  0.0%-2349.5%-2682.5%-19866.2%
   
Basic EPS   [+] ($1.84)($15.69)($24,041.44)
Diluted EPS   [+] ($1.84)($15.69)($24.04)
   
Shares outstanding (basic)   [+] 135.913.30.0
Shares outstanding (diluted)   [+] 135.913.35.4
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy